资料显示，湖南华纳大药厂股份有限公司位于湖南省长沙市岳麓区麓天路28号C6-C7栋，成立日期2001 年4月30日，上市日期2021年7月13日，公司主营业务涉及化学原料药、化学药制剂和中药制剂的研发、 生产与销售。主营业务收入构成为：制剂产品73.19%，原料药及中间体25.22%，技术服务1.52%，植物 提取物及食品0.06%，其他0.01%。 截至9月30日，华纳药厂股东户数6416.00，较上期减少11.83%；人均流通股20467股，较上期增加 13.42%。2025年1月-9月，华纳药厂实现营业收入10.86亿元，同比增长1.55%；归母净利润2.07亿元，同 比增长30.75%。 分红方面，华纳药厂A股上市后累计派现2.91亿元。近三年，累计派现2.25亿元。 1月29日，华纳药厂跌0.41%，成交额1.92亿元。两融数据显示，当日华纳药厂获融资买入额1832.34万 元，融资偿还4229.33万元，融资净买入-2396.99万元。截至1月29日，华纳药厂融资融券余额合计2.52 亿元。 融资方面，华纳药厂当日融资买入1832.34万元。当前融资余额2.52亿元，占流通市值的3.98%，融资余 ...

证券日报网讯 1月28日，华纳药厂发布公告称，公司于2025年12月10日召开第四届董事会第四次会议和 第四届监事会第四次会议、2025年12月26日召开2025年第二次临时股东大会，审议通过了《关于变更注 册资本、取消监事会、调整董事会人数、修订并办理工商变更登记的议案》。近日，公司已完成上述事 项的工商变更登记及变更后《公司章程》的备案手续，并取得了长沙市市场监督管理局换发的《营业执 照》。 （编辑 任世碧） ...

湖南华纳大药厂股份有限公司 关于完成工商变更登记并换发营业执照的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 湖南华纳大药厂股份有限公司（以下简称"公司"）于 2025 年 12 月 10 日召 开第四届董事会第四次会议和第四届监事会第四次会议、2025 年 12 月 26 日召 开 2025 年第二次临时股东大会，审议通过了《关于变更注册资本、取消监事会、 调整董事会人数、修订<公司章程>并办理工商变更登记的议案》。具体内容详见 公司于 2025 年 12 月 11 日在上海证券交易所网站（www.sse.com.cn）披露的《湖 南华纳大药厂股份有限公司关于变更注册资本、取消监事会、调整董事会人数、 修订<公司章程>并办理工商变更登记及修订、制定公司部分治理制度的公告》 （公告编号：2025-090）。 近日，公司已完成上述事项的工商变更登记及变更后《公司章程》的备案手 续，并取得了长沙市市场监督管理局换发的《营业执照》，变更后的具体登记事 项如下： 名称：湖南华纳大药厂股份有限公司 证券代码：688799 证 ...

华纳药厂表示，公司于2025年3月向国家药品监督管理局递交该产品的上市许可申请并获得受理。经审 慎研究，结合研发策略，公司决定主动撤回本次药品注册申请。该药品注册申请的主动撤回并终止不会 对公司当期及未来生产经营与业绩产生重大影响。 北京商报讯（记者 丁宁）1月27日晚间，华纳药厂（688799）发布公告称，公司收到国家药品监督管理 局核准签发的《药品注册申请终止通知书》，同意公司撤回利多卡因凝胶贴膏的注册申请。 公告显示，利多卡因凝胶贴膏主要用于缓解带状疱疹后遗神经痛，用于无破损皮肤。 ...

公司于 2025 年 3 月向国家药品监督管理局递交该产品的上市许可申请并获 得受理。经审慎研究，结合研发策略，公司决定主动撤回本次药品注册申请。 该药品注册申请的主动撤回并终止不会对公司当期及未来生产经营与业绩 产生重大影响。敬请广大投资者注意投资风险。 特此公告。 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，湖南华纳大药厂股份有限公司（以下简称"公司"）收到国家药品监 督管理局核准签发的《药品注册申请终止通知书》，同意公司撤回利多卡因凝胶 贴膏的注册申请。现将相关情况公告如下： | 药品名称 | 注册分类 | 受理号 | 通知书编号 | 审批结论 | | --- | --- | --- | --- | --- | | | | CYHS2501139 | 2026L00051 | 根据《药品注册管理办法》第八十九条以 及申请人的撤回申请《关于撤回利多卡因 凝胶贴膏药品注册上市许可申请的请示报 | | 利多卡因 | 化学药品 | | | | | 凝胶贴膏 | 4 类 | | | | | | | | | 告》，同意本 ...

每经AI快讯，1月27日，华纳药厂(688799.SH)公告称，公司收到国家药品监督管理局核准签发的《药品 注册申请终止通知书》，同意公司撤回利多卡因凝胶贴膏的注册申请。该产品主要用于缓解带状疱疹后 遗神经痛，用于无破损皮肤。公司于2025年3月向国家药品监督管理局递交该产品的上市许可申请并获 得受理，但经审慎研究，结合研发策略，公司决定主动撤回本次药品注册申请。该药品注册申请的主动 撤回并终止不会对公司当期及未来生产经营与业绩产生重大影响。 ...

| 代码 | 名称 | | 涨幅% ↓ | 总市值 | 年初至今涨幅% | | --- | --- | --- | --- | --- | --- | | 300436 | 广生堂 | 1 | 20.00 | 153亿 | 8.00 | | 301093 | 中三股份 | 资 | 12.00 | 138亿 | 63.89 | | 600774 | 汉商集团 * | | 10.00 | 34.08亿 | 26.37 | | 300683 | 海特生物 | 资 | 7.92 | 43.71亿 | 20.41 | | 688759 | 必贝特-U | 1 | 6.64 | 249亿 | 90.09 | | 300204 | 舒泰神 | 1 | 5.78 | 136亿 | 4.58 | | 688222 | 成都先导 | 中 | 5.42 | 138亿 | 46.78 | | 000078 | 海王生物 | 1 | 5.23 | 101亿 | 10.40 | | 600998 | 九州通 | 1 | 4.71 | 280亿 | 8.59 | | 301230 | 泓博医药 | | 4.60 | 67.60亿 | 62 ...

Group 1 - Warner Pharmaceutical's stock increased by 5.52%, reaching 49.88 CNY per share, with a trading volume of 177 million CNY and a turnover rate of 2.77%, resulting in a total market capitalization of 6.55 billion CNY [1] - The company, established on April 30, 2001, and listed on July 13, 2021, is located in Changsha, Hunan Province, and specializes in the research, production, and sales of chemical raw materials, chemical drug formulations, and traditional Chinese medicine formulations [1] - The revenue composition of the company includes 73.19% from formulation products, 25.22% from raw materials and intermediates, 1.52% from technical services, 0.06% from plant extracts and food, and 0.01% from other sources [1] Group 2 - Anxin Fund's Anxin Medical Health Stock A (010709) holds 1.2294 million shares of Warner Pharmaceutical, unchanged from the previous period, representing 0.94% of the circulating shares, with an estimated floating profit of approximately 3.2088 million CNY [2] - The fund, established on January 12, 2021, has a current scale of 362 million CNY, with a year-to-date return of 10.02%, ranking 1184 out of 5542 in its category, and a one-year return of 74.07%, ranking 305 out of 4256 [2] - The fund manager, Chi Chenshen, has been in position for 5 years and 12 days, managing a total asset scale of 1.691 billion CNY, with the best fund return during his tenure at 57.47% and the worst at 53.57% [3] Group 3 - Anxin Medical Health Stock A (010709) has Warner Pharmaceutical as its eighth largest holding, with 1.2294 million shares, unchanged from the previous period, accounting for 3.47% of the fund's net value, and an estimated floating profit of approximately 3.2088 million CNY [4]

Core Viewpoint - The significant price discrepancies between hospital and retail pharmacy prices for the same medication raise concerns about the effectiveness of centralized procurement policies and the trust in public healthcare systems [2][3]. Price Discrepancies - A specific example highlights that the price of pediatric calcium carbonate D3 granules is 34.93 yuan in a hospital, while the same product is priced at approximately 19 yuan in pharmacies and e-commerce platforms, resulting in a price difference of 15.93 yuan [2]. - The price of the same medication can vary significantly across different sales channels, with instances of hospital prices being higher than retail prices and vice versa [3]. Centralized Procurement Issues - The pediatric calcium carbonate D3 granules were included in centralized procurement in 2022, with a winning bid price of 3.795 yuan per bag, which was further reduced to 2.495 yuan per bag in subsequent procurement rounds [3][4]. - Despite the centralized procurement prices, hospitals are reportedly selling the medication at prices that exceed these rates, indicating a disconnect between procurement prices and actual supply costs [4][6]. Factors Contributing to Price Differences - The pricing discrepancies are attributed to several factors, including the dynamic nature of market conditions, hidden service costs in hospitals, and the competitive pricing strategies of retail pharmacies and e-commerce platforms [6][7]. - Regulatory gaps and insufficient monitoring of real-time prices across different sales channels contribute to the lack of price uniformity [8]. Regulatory Responses - The National Medical Insurance Administration has initiated measures to address price discrepancies, including monitoring and comparing prices across various platforms to ensure compliance with procurement guidelines [10][11]. - Local governments are also implementing stricter regulations to align hospital prices with those of retail pharmacies and e-commerce platforms, emphasizing the need for transparency and fairness in drug pricing [11][12]. Future Directions - Experts suggest that a more transparent pricing mechanism is necessary, potentially resembling e-commerce platforms, to allow for direct price comparisons and foster competition among pharmaceutical companies [12].

Core Viewpoint - The significant price discrepancies between hospital and retail prices for pediatric calcium D3 granules raise concerns about the effectiveness of centralized procurement policies and public trust in healthcare systems [1][3][8]. Price Discrepancies - Pediatric calcium D3 granules sold in hospitals can be priced at 34.93 yuan for a 14-bag pack, while the same product is available for approximately 19 yuan in pharmacies and e-commerce platforms, resulting in a price difference of 15.93 yuan [1]. - Similar price discrepancies exist for other medications, with examples showing hospital prices exceeding retail prices and vice versa [2]. Centralized Procurement and Pricing - The pediatric calcium D3 granules were included in centralized procurement in 2022, with the winning bid price set at 3.795 yuan per bag, which was later reduced to 2.495 yuan per bag in 2025 [3][4]. - Despite the centralized procurement prices, hospitals are selling the product at prices that deviate from these rates, indicating a disconnect between procurement prices and actual supply costs [3][8]. Factors Contributing to Price Differences - The price differences can be attributed to several factors, including the dynamic nature of market conditions, hidden service costs in hospitals, and the competitive pricing strategies of retail and online pharmacies [9][10]. - Regulatory gaps and the lack of real-time monitoring of drug prices contribute to the persistence of these discrepancies [10][11]. Regulatory Responses - The National Medical Insurance Administration has acknowledged these pricing issues and is working on measures to align hospital prices with those of retail pharmacies and e-commerce platforms [11][13]. - Local governments are also implementing stricter regulations to ensure that procurement prices are consistent with market prices, with penalties for non-compliance [14][15]. Future Directions - Experts suggest that a transparent pricing mechanism similar to e-commerce platforms should be established to allow for better price comparisons and competition among suppliers [17].